Research graph
References from P4HA1 sustains endocrine resistance in luminal breast cancer via regulation of cellular stress. Local targets link to admitted publications; unresolved targets remain external evidence.
: Molecular Biology of Prolyl 4-Hydroxylase
10.1111/j.1749-6632.1990.tb17925.x · 1990 · External reference
10.3109/10409231003627991
10.3109/10409231003627991 · External reference
10.1074/jbc.273.11.5989
10.1074/jbc.273.11.5989 · External reference
10.1016/s0945-053x(98)90009-9
10.1016/s0945-053x(98)90009-9 · External reference
: Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data
10.3390/cancers12071788 · 2020 · External reference
10.3389/fcell.2021.754580
10.3389/fcell.2021.754580 · External reference
10.1158/0008-5472.can-12-3963
10.1158/0008-5472.can-12-3963 · External reference
10.1038/s41467-018-06893-9
10.1038/s41467-018-06893-9 · External reference
10.1371/journal.pone.0124964
10.1371/journal.pone.0124964 · External reference
10.1016/s0140-6736(11)60993-8
10.1016/s0140-6736(11)60993-8 · External reference
10.1016/j.ccell.2020.03.009
10.1016/j.ccell.2020.03.009 · External reference
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice
10.1016/j.critrevonc.2016.02.008 · 2016 · External reference
10.1007/s10549-018-5023-4
10.1007/s10549-018-5023-4 · External reference
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
10.1186/s43556-024-00239-2 · 2025 · External reference
10.1177/17588359221113694
10.1177/17588359221113694 · External reference
10.1210/endocr/bqaf127
10.1210/endocr/bqaf127 · External reference
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study
2025 · External reference
: MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen
1997 · External reference
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
10.1038/s41416-018-0354-9 · 2019 · External reference
10.1007/s10549-014-2878-x
10.1007/s10549-014-2878-x · External reference
10.1007/s10549-009-0674-9
10.1007/s10549-009-0674-9 · External reference
10.1200/jco.2013.54.1870
10.1200/jco.2013.54.1870 · External reference
10.1039/c0cs00203h
10.1039/c0cs00203h · External reference
10.1042/bj3530333
10.1042/bj3530333 · External reference
: Endoplasmic reticulum stress: molecular mechanism and therapeutic targets
10.1038/s41392-023-01570-w · 2023 · External reference
10.1038/ncb0311-184
10.1038/ncb0311-184 · External reference
10.1074/jbc.m406933200
10.1074/jbc.m406933200 · External reference
10.1186/s13046-018-0935-8
10.1186/s13046-018-0935-8 · External reference
10.18632/oncotarget.19277
10.18632/oncotarget.19277 · External reference
10.1096/fj.13-247353
10.1096/fj.13-247353 · External reference
Unresolved reference
External reference
10.1158/1078-0432.ccr-10-1745
10.1158/1078-0432.ccr-10-1745 · External reference
: Excessive Oxidative Stress Contributes to Increased Acute ER Stress Kidney Injury in Aged Mice
2019 · External reference
10.2337/dc13-2018
10.2337/dc13-2018 · External reference
10.18632/oncotarget.15393
10.18632/oncotarget.15393 · External reference
10.1089/ars.2014.5851
10.1089/ars.2014.5851 · External reference
: ROS mediated ER stress induces Bax-Bak dependent and independent apoptosis in response to Thioridazine
10.1016/j.biopha.2018.06.123 · 2018 · External reference
Induction of Endoplasmic Reticulum Stress via Reactive Oxygen Species Mediated by Luteolin in Melanoma Cells
2016 · External reference
10.1038/s12276-020-0384-2
10.1038/s12276-020-0384-2 · External reference
10.1016/j.pharmthera.2021.107916
10.1016/j.pharmthera.2021.107916 · External reference
10.1042/bj20130282
10.1042/bj20130282 · External reference
10.1007/s00109-021-02136-5
10.1007/s00109-021-02136-5 · External reference
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
10.1159/000508675 · 2020 · External reference
10.3389/fendo.2019.00547
10.3389/fendo.2019.00547 · External reference
10.3390/ijms18020382
10.3390/ijms18020382 · External reference
10.1101/2025.08.18.670862
10.1101/2025.08.18.670862 · External reference
10.1158/0008-5472.can-15-2616
10.1158/0008-5472.can-15-2616 · External reference
10.3390/ijms17030327
10.3390/ijms17030327 · External reference
10.1371/journal.pone.0132285
10.1371/journal.pone.0132285 · External reference
10.1016/j.canlet.2021.07.015
10.1016/j.canlet.2021.07.015 · External reference
: Combining lapatinib and palbociclib inhibits cell proliferation and invasion via AKT signaling pathway in endocrine-resistant breast cancer cells
10.1007/s12032-023-02290-5 · 2024 · External reference
